Table 7.
Multivariable Logistic Regression Models for HP Disorders and Physical Health Outcomes
| Physical Health Outcome | Clinical Outcome (Yes) | GHD | TSHD | Untreated LH/FSHD | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GHD | No GHD | Multivariable Analysis | TSHD | No TSHD | Multivariable Analysis | LH/FSHD | No LH/FSHD | Multivariable Analysis | ||||||||
| No. (%) | No. (%) | No. (%) | OR | 95% CI | P Value | No. (%) | No. (%) | OR | 95% CI | P Value | No. (%) | No. (%) | OR | 95% CI | P Value | |
| Short stature (n = 2231)a | 209 (9.4) | 105 (23.1) | 104 (5.9) | 3.50 | 2.54 to 4.83 | <0.0001 | 33 (28.2) | 176 (8.3) | 1.90 | 1.16 to 3.10 | 0.01 | 16 (20.5) | 193 (9.0) | 0.95 | 0.50 to 1.79 | 0.87 |
| Obesity (n = 2210)b | 825 (37.3) | 199 (44.5) | 626 (35.5) | 1.20 | 0.94 to 1.54 | 0.15 | 48 (41.4) | 777 (37.1) | 0.83 | 0.54 to 1.27 | 0.39 | 49 (63.6) | 776 (36.4) | 2.62 | 1.56 to 4.41 | 0.0003 |
| Low BMD (n = 2035)c | 521 (25.6) | 164 (40.5) | 357 (21.9) | 2.16 | 1.68 to 2.78 | <0.0001 | 49 (47.6) | 472 (24.4) | 1.54 | 0.98 to 2.42 | 0.06 | 32 (55.2) | 489 (24.7) | 2.40 | 1.35 to 4.26 | 0.003 |
| Hypertension (n = 2203)d | 352 (16.0) | — | — | — | — | — | 16 (13.9) | 336 (16.1) | 1.09 | 0.60 to 1.97 | 0.78 | 19 (24.7) | 333 (15.7) | 1.13 | 0.61 to 2.08 | 0.70 |
| Dyslipidemia (n = 2150)e | 112 (5.2) | — | — | — | — | — | 7 (6.3) | 105 (5.2) | 1.31 | 0.56 to 3.07 | 0.53 | 9 (11.8) | 103 (5.0) | 1.49 | 0.67 to 3.30 | 0.32 |
| Abnormal glucose metabolism (n = 2265)f | 140 (6.2) | 40 (7.9) | 100 (5.7) | 1.42 | 0.92 to 2.18 | 0.11 | 13 (8.0) | 127 (6.0) | 1.31 | 0.68 to 2.54 | 0.43 | — | — | — | — | — |
| Frailty (n = 2064)g | 118 (5.7) | 41 (9.7) | 77 (4.7) | 1.87 | 1.21 to 2.91 | 0.01 | 14 (13.5) | 104 (5.3) | 1.87 | 0.96 to 3.65 | 0.07 | 9 (13.0) | 109 (5.5) | 1.57 | 0.71 to 3.50 | 0.26 |
| Poor exercise tolerance (n = 2087)h | 170 (8.2) | 49 (11.9) | 121 (7.2) | 1.51 | 1.02 to 2.23 | 0.04 | 18 (18.2) | 152 (7.7) | 2.15 | 1.17 to 3.95 | 0.01 | 11 (16.2) | 159 (7.9) | 1.44 | 0.69 to 3.03 | 0.33 |
| Cardiomyopathy (n = 2277)i | 139 (6.1) | 21 (4.2) | 118 (6.7) | 0.80 | 0.48 to 1.34 | 0.40 | 4 (2.5) | 135 (6.4) | 0.87 | 0.30 to 2.54 | 0.80 | — | — | — | — | — |
Short stature was adjusted for craniospinal radiotherapy and stem cell transplantation.
Increased body mass index was adjusted for sex, ethnicity/race, age at SJLIFE, cranial radiation therapy and age at cancer diagnosis.
Low BMD was adjusted for obesity (i.e., body mass index >30 kg/m2), prednisone equivalent dose, and total body irradiation.
Hypertension was adjusted for sex, age at SJLIFE, ethnicity/race, obesity, and age at cancer diagnosis.
Dyslipidemia was adjusted for sex, age at SJLIFE, ethnicity/race, obesity, and age at cancer diagnosis.
Abnormal glucose metabolism was adjusted for sex, age at SJLIFE, ethnicity/race, obesity, and age at cancer diagnosis.
Poor exercise tolerance was adjusted for sex, age at SJLIFE, and obesity.
Frailty was adjusted for age at cancer diagnosis and smoking status.
Cardiomyopathy was adjusted for sex, age at SJLIFE, ethnicity/race, obesity, previous anthracycline use, and chest irradiation.